These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16760272)

  • 21. Epidermal growth factor receptor as a major anticancer drug target.
    Caponigro F; Milano A; Ottaiano A; Iaffaioli RV
    Expert Opin Ther Targets; 2006 Dec; 10(6):877-88. PubMed ID: 17105374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
    Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
    Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
    Press MF; Lenz HJ
    Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B; Hagekyriakou J; Trivett MK; Stacker SA; McArthur GA; Cullinane C
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(3):713-23. PubMed ID: 12573759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging targeted therapies for breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel targeted radiosensitisers in cancer treatment.
    Zaidi SH; Huddart RA; Harrington KJ
    Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment.
    Nayarisseri A; Singh SK
    Curr Top Med Chem; 2019; 19(3):178-179. PubMed ID: 30950335
    [No Abstract]   [Full Text] [Related]  

  • 33. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
    Zajac M; Muszalska I; Jelinska A
    Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor inhibition: conflicting roles in tumor growth.
    Saranadasa M; Wang ES
    Cytokine; 2011 Feb; 53(2):115-29. PubMed ID: 20708948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy in colorectal cancer: current status and future challenges.
    Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
    Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.
    Masuda M; Suzui M; Lim JT; Deguchi A; Soh JW; Weinstein IB
    J Exp Ther Oncol; 2002; 2(6):350-9. PubMed ID: 12440226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.